{"organizations": [], "uuid": "e15df2f12d04a3f0737f453a80c307c0b1f831a1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180220.html", "section_title": "Archive News &amp; Video for Tuesday, 20 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-puretech-says-follica-rain-pivotal/brief-puretech-says-follica-rain-pivotal-study-expected-to-commence-following-completion-of-ongoing-optimisation-study-idUSFWN1QA093", "country": "US", "domain_rank": 408, "title": "BRIEF-Puretech Says ‍Follica Rain Pivotal Study Expected To Commence Following Completion Of Ongoing Optimisation Study​", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.438, "site_type": "news", "published": "2018-02-20T15:33:00.000+02:00", "replies_count": 0, "uuid": "e15df2f12d04a3f0737f453a80c307c0b1f831a1"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-puretech-says-follica-rain-pivotal/brief-puretech-says-follica-rain-pivotal-study-expected-to-commence-following-completion-of-ongoing-optimisation-study-idUSFWN1QA093", "ord_in_thread": 0, "title": "BRIEF-Puretech Says ‍Follica Rain Pivotal Study Expected To Commence Following Completion Of Ongoing Optimisation Study​", "locations": [], "entities": {"persons": [{"name": "akili", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters) - puretech health plc", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 20 (Reuters) - Puretech Health Plc:\n* ‍FOLLICA RAIN PIVOTAL STUDY IS EXPECTED TO COMMENCE FOLLOWING COMPLETION OF AN ONGOING OPTIMISATION STUDY​\n* ‍OVER NEXT 12 MONTHS, REGULATORY FILINGS ANTICIPATED FROM BOTH AKILI AND GELESIS WITH FDA IN FIRST HALF OF 2018​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-20T15:33:00.000+02:00", "crawled": "2018-02-21T21:38:38.008+02:00", "highlightTitle": ""}